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Recently, using a proteomic approach we have identified the corepressor Alien as a novel interacting factor of the cell cycle regulator E2F1.
Unclear was whether this interaction influences cell proliferation and endogenous E2F1 target gene expression. Here, we show by chromatin
immunoprecipitation (ChIP) that Alien is recruited in vivo to the E2F binding sites present in the E2F1 gene promoter, inhibits the transactivation
of E2F1 and represses endogenous E2F1 gene expression. Interestingly, using synchronized cells to assess the expression of Alien profile during
cell cycle the levels of endogenous Alien are increased during G1, G1/S and G2 phase. Furthermore, stable transfection of Alien leads to reduction
of cell proliferation. Thus, the data suggest that Alien acts as a corepressor for E2F1 and is involved in cell cycle regulation.
© 2007 Elsevier B.V. All rights reserved.Keywords: Corepressor; Gene repression; Transcription; E2F1; Cell cycle1. Introduction
The transcription factor E2F1 plays a crucial role in the
regulation of cell-cycle progression at the G1-S transition [1–3].
Furthermore, E2F1 is associated with DNA repair and apoptosis
[4–8]. In line with that, deregulation of the transcription factor
E2F1 is a common event in most human cancers. E2F1 is a
transcriptional activator and a member of the E2F transcription
factor family that regulates cell cycle progression ([7,9–11]). AsAbbreviations: ChIP, chromatin immunoprecipitation; CoIP, co-immuno-
precipitation; IB, immunoblot; IP, immunoprecipitation; MS, Mass spectrom-
etry; pRB, retinoblastoma protein; T3, thyroid hormone; TR, thyroid hormone
receptor; tTA, Tet activator; VDR, vitamin D3 receptor
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doi:10.1016/j.bbamcr.2007.04.017the other members, E2F1 regulates the expression of a number
of cell cycle regulatory factors. Interestingly, E2F1 itself
induces the expression of its gene by E2F binding sites located
in the promoter region [12]. E2F1 forms protein complexes with
other cellular proteins that are known or inferred to regulate cell
cycle. E2F1 mediates its transcriptional activation through
binding to coactivators ([13,14]). Moreover, it has been shown
that E2F-1 transcriptional activity, DNA binding, and protein
stability are regulated by protein acetylation [15].
Other interacting factors such as the retinoblastoma protein
(pRB) and the pocket domain protein p107 are known to bind
directly to and repress E2F1 transcriptional activation [16–19].
One mechanism of pRB-mediated repression of E2F1 is
through association with histone deacetylase activity (HDAC)
and histone methyltransferase activity [20,21].
Endogenous E2F1 message abundance is regulated in a cell
cycle dependent manner. E2F1 seems not be abundantly present
in resting cells [22]. Deregulation of E2F1 is a common event in
many human cancers [4] and overexpression of E2F1 can
advance cells from quiescence into S-phase [22,23,7] indicating
that lack of E2F1 downregulation and lack of E2F1-mediated
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Analysis of the cell cycle dependent expression profile of E2F1
after growth stimulation suggests it is expressed throughout the
cell cycle with highest expression detected in S-phase [24,25].
Interestingly, a complex containing E2F1 and the corepres-
sor Alien was very recently detected [19]. This interaction was
confirmed by in vitro binding assays suggesting a direct binding
of E2F1 and Alien. Alien was previously characterized as a
corepressor for specific members of the nuclear hormone
receptor superfamily including the thyroid hormone receptor
(TR), vitamin D3 receptor (VDR) and DAX1 [26–28]. Alien
interacts in a hormone-sensitive manner with TR and VDR and
enhances transcriptional repression. One mechanism of Alien-
mediated repression was shown to be mediated by HDAC
activity [26]. Here, we followed the notion whether Alien might
act as a corepressor for E2F1 transcriptional function.
2. Experimental procedures
2.1. Cell culture and DNA transfection
Cell lines used here were cultured in DMEM supplemented with 10% fetal
bovine serum whereas the LNCaP cell line was cultivated in RPMI and
supplemented with 10% fetal bovine serum. Transient transfection experiments
were performed according to Moehren et al. [29]. The experiments have been
repeated at least three times. Tetracycline regulation was performed using the
NIH3T3-S2-6 cells [30] containing the Tet-activator (tTA). Cells were grown in the
presence of 0.5 μg/ml tetracycline and 0.5 mM histidinol [30] and infected
retrovirally with pHRS vectors using cells expressing the ecotropic receptor [31].
Stable selected cell clones were selected 2 days post transduction with 2 μg/ml
puromycin. Cell numbers were counted in the absence or presence of tetracycline
(0.5 mg/ml). Stable transfection experiments with LNCaP cells [32] were performed
using DOTAP transfection reagent according to the manufacturer's protocol (Carl
Roth GmbH, Karlsruhe, Germany). Serum-free RPMI medium (Invitrogen) was
used to transfect cells with pETE-Hyg control plasmid [32] or pETE-Hyg-Alien
expression vector (5 μg each for a 10-cm dish). 24 h after transfection, the medium
was changed and replaced with RPMI containing 5% serum. After a further
cultivation of 48 h, selection of transfected LNCaP cells was accomplished by
addition of 200 μg/ml hygromycin into the culture medium. Cells were cultured for
approximately 2weeks, changing themedium and hygromycin every 2–3 days until
untransfected control cells were completely killed by the selection.
2.2. ChIP
After 3 days of cultivation of LNCaP cells with RPMI supplemented with 2%
charcoal treated FCS, the proteins were cross-linked to DNA by adding
formaldehyde directly to the medium resulting in a final concentration of 1% at
37 °C for 10 min. Cross-linking within the cells was stopped by adding glycine at a
final concentration of 0.125 M and incubating at room temperature (RT) for 5 min
on a rocking platform.Cells thenwere rinsed twicewith ice-cold PBS, collected into
ice cold PBS supplemented with a protease inhibitor cocktail (Roche Diagnostics
GmbH, Mannheim, Germany). After centrifugation the cell pellets were
resuspended in lysis buffer (1% SDS, 10 mM EDTA 50 mM Tris–HCl pH 8.0
and protease inhibitors). The lysates were sonicated on ice 10 times, 10 sec at 10%
of maximum of power (Branson W-250/W), to yield DNA fragments of 500 bp in
length. After centrifugation supernatants were collected and diluted in ChIP dilution
buffer (0.01% Triton X-100, 2 mM EDTA, 150 mM NaCl, 20 mM Tris–HCl pH
8.0) followed by preclearing with 30 μl of salmon sperm DNA/protein A agarose
50% slurry (Upstate Biotechnology, Lake Placid, NY) for 1 h at 4 °Cwith agitation.
Immunoprecipitationwas performed overnight at 4 °Cwith the rabbit anti-androgen
receptor antibody (Upstate Biotechnology) or with Alien specific antibody (PEP
AK-2 [26]. The immunocomplexes were collected with 30 μl of salmon sperm
DNA/protein A agarose 50% slurry for another 2 h with rotation at 4 °C. Agarose
beads were pelleted by centrifugation andwashed sequentially for 10min eachwith1 ml of the following buffers: light salt wash buffer (0.1% SDS, 1% Triton X-100,
2 mM EDTA, 20 mM Tris–HCl, pH 8, and 150 mM NaCl), high salt wash buffer
(0.1% SDS, 1% Triton X-100, 2 mMEDTA, 20 mMTris–HCl, pH 8, and 500mM
NaCl), and LiCl wash buffer (0.25 M LiCl, 1% NP-40, 1% deoxycholate, 1 mM
EDTA, and 10mMTris–HCl, pH 8). Finally, the beadswerewashed two timeswith
TE buffer (10 mM Tris–HCl, 1 mM EDTA, pH 8). The immunocomplexes were
eluted twice from the beads by adding freshly prepared elution buffer (1% SDS,
0.1MNaHCO3). Eluates were pooled and the cross-linkingwas reversed by adding
NaCl to final concentration of 200 mM and heated at 65 °C overnight. The
remaining proteins and RNA were digested by adding proteinase K (final
concentration 40 μg/ml) and RNase A (20 μg/ml) respectively and incubating at
55 °C for 3 h. The DNA fragments were purified with a DNA purification kit
(QIAquick PCR Purification Kit, Qiagen, Hilden, Germany). For PCR, 5 μl out of
50 μl DNA was used in 34 cycles of amplification with addition of betain (final
concentration 1M). The primer sequences and the positions from transcription start
sites are as follows:
E2F elements forward (−1429 bp): 5′ AGGAACCGCCGCCGTTGTT-
CCCGT 3′
E2F elements reverse (−1247 bp): 5′ GCTGCCTGCAAAGTCCCGGC-
CACT 3′
E2F1-upstream forward (−206 bp): 5′ CAGAACCGTGGTCTCCTTGT-
CACAGTC 3′
E2F1-upstream reverse (−105 bp): 5′ TCACTTCCTCTATTGCCCA-
CTGCTGCC 3′
3. Quantitative real-time PCR (qRT-PCR)
2×106 LNCaP, as control, or LNCaP-Alien cells were
seeded out per 10 cm dish in RPMI containing 10% charcoal-
stripped FCS. 72 h later medium was replaced with fresh RPMI
(10% charcoal-stripped FCS). RNA was isolated 24 h after
hormone induction using peqGOLD TriFast (Peqlab) according
to the manufacturer's protocol. 0.88 μg of RNA were used per
sample in an one-step qRT-PCR reaction using the SuperScript
III Platinum SYBR Green One-Step qRT-PCR Kit (Invitrogen)
with these primer sequences:
E2F1-forward: 5′CAAGAAGTCCAAGAACCACATCC3′
E2F1-reverse: 5′AGATATTCATCAGGTGGTCCAGC3′
beta-actin-forward: 5′ACAGAGCCTCGCCTTTGCCGA3′
beta-actin-reverse: 5′CACGATGGAGGGGAAGACG3′
Data analysis was done by normalizing to beta-actin mRNA
levels as described [33].
3.1. Synchronization of eukaryotic cells
To stop HeLa cells in different cell cycle stages, the cells
were submitted to different treatments as described in Krek
et al. [34]. For these assays, two equal 80% confluent 10-cm
dishes were used for each cell cycle phase. One dish of each
duplicate lysed for protein extracts for Western blot analysis,
and the other one was ethanol-fixed for FAC-Scan analysis as
described below. Mitosis: To stop cells in mitosis they were
treated 16–18 h with 50 ng/ml nocodazol (Sigma). Mitotic
cells with round morphology were detached by mitotic shake-
off, harvested by centrifugation (10 min 1000 rpm, RT) from
the medium. G1-phase: HeLa cells were synchronized in G1-
phase by mimosine treatment (0.5 mM, for 24 h, Sigma). G1/S-
phase: Treatment of the HeLa cells with hydroxy urea (Sigma;
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cell cycle. S-phase/G2 phase: To stop HeLa cells in S-phase,
the cells were submitted to thymidine block (Sigma; 2.5 mM
over night). The cells were then washed twice with PBS to
remove the thymidine and to release the cell cycle block and
normal medium was applied. After growth of the cells for 2 h
the S-phase was reached, after 8 h release the cells were in
G2-phase.
3.2. Fixation and FAC-Scan analysis
To assay cell cycle stage of HeLa cells, the cells were harvested
and ethanol-fixed. Thereafter, the medium was recollected and
centrifuged (5 min, 2500 rpm, RT) to obtain detached apoptotic
cells. The remaining cells were harvested using trypsin and cen-
trifuged as mentioned above. The two cell pellets were pooled and
the resulting pellet was washed twice in PBS. To fix the cells, 1 ml
of ice-cold 70% ethanol (−20 °C) was added slowly, the cells were
resuspended carefully and the probes were incubated for 15–
30 min on ice. After that, the cells were spun down (pulse) and
washed again with PBS, resuspended in 200 μl PBS and treated for
30 min at 37 °C with 1 μl RNase-A (10 μg/μl). Then, DNAwas
stained with 50 μg propidium iodide (PI, Sigma; 10 μg/μl) and cell
cycle profile was acquired in a FACS Aria Cytometer (BD
Bioscience).
3.3. Co-immunoprecipitation
The Co-IP assays were carried out as described [35]. Briefly,
a specific antibody or, as negative control, normal rabbit IgG
were bound on protein A-agarose beads. Crude extract (250 μl)
from U-2OS cells was incubated with the antibody loaded
beads for 1 h at 4 °C. Then the resins were washed three times
with Co-IP buffer containing 20 mM HEPES/KOH pH 8.0,
50 mM KCl, 0.1 mM EDTA and 0.05% CHAPS. Bound
proteins were subjected to 10% SDS-PAGE and detected by
immunoblotting. (For details concerning used antibodies see
figure legends).
3.4. Transient transfection
C33A cells were cultured and transfected in DMEM
supplemented with 10% FCS. Cells were seeded 48 h prior to
transfection into 6 well plates at a density of 240000 cells per
well. Medium was changed 9 h prior to transfection. DNAwas
introduced according to the CaPO4 transfection method
described [29]. 0.5 μg E2F1-promoter-luc, E2F1mut-promot-
er-luc reporter-plasmids [12], or pUAS4xTATA-Luc [36],
0.7 μg indicated expression-vector and, 0.3 μg pCMV-LacZ
per well were used and total amount of DNA was adjusted to
5.4 μg with calf thymus DNA. The expression vector for Gal-
E2F1, expressing the E2F1 residues 284–437, was kindly
provided by Dr. Bentley [37]. 24 h past transfection cells were
washed 3 times with 2 ml PBS and medium was changed. After
further 48 h of culturing cells were harvested and lysed to
measure luciferase as well as beta-galactosidase activity for
normalization and transfection efficiency control.4. Results
4.1. Alien is recruited to the E2F1 promoter in vivo
The E2F1 gene expression is regulated by binding of E2F
transcription factors to the E2F1 promoter [12]. Previouslywe have
described the in vivo interaction of E2F1with Alien in a proteomic
approach using the combined techniques of immunoprecipitation
and mass spectrometry (MS), which is confirmed in vitro and by
co-immunoprecipitation ([19] and Fig. 1A). Immunoprecipitation
with either an E2F1 or reciprocally with anAlien antibody [26] and
subsequent immunoblot with E2F1 or Alien antibody, respectively,
detected E2F1 (Fig. 1A, upper panel) or Alien (Fig. 1A, lower
panel) as co-immunoprecipitate. Similar results were obtained
using an E2F3 specific antibody suggesting that Alien is also
complexed with E2F3 (data not shown and [19]). These data
suggest an in vivo interaction of E2F1 with the corepressor Alien.
Unclear was whether Alien is recruited in vivo to chroma-
tinized DNA. For that purpose we employed the ChIP-
technique. Immunoprecipitation of Alien coprecipitated the
genomic sequence of the E2F binding sites of the E2F1
promoter, which was detected by PCR (Fig. 1B upper panel).
Unspecific antibodies, as negative controls, did not show a
similar PCR band suggesting that Alien is recruited to the E2F1
promoter in vivo. Another negative control involved the analysis
of upstream sequences of the E2F1 gene. Compared to the input,
there is only a weak band observed using the anti-Alien antibody
(Fig. 1B lower panel). The obtained data suggest that Alien is
only weakly recruited to the upstream chromatin sites indicating
a significant recruitment of Alien to the proximal E2F1 promoter
part, which contains E2F binding sites.
4.2. Alien inhibits E2F-1 gene expression in vivo
To detect in a first step whether Alien influences the
transcriptional activity of E2F1, E2F-responsive reporter assays
were performed. For that purpose, the wildtype E2F1 promoter-
luciferase reporter containing the E2F-binding sites from the
E2F1 promoter together with expression plasmids coding for
Alien or, as a control, the empty vector were transfected in
C33A cells lacking the expression of functional retinoblastoma
protein (Fig. 2A). As a further control, a reporter with the
mutated E2F-binding sites within the same promoter context
was employed [12]. Expression of Alien inhibited the reporter
activity. As expected, using as control the reporter mutated at
the E2F binding sites, which exhibited weaker transcriptional
activity (data not shown), the co-expression of Alien did not
repress as strongly as using the wildtype E2F binding sites (Fig.
2A). This suggests that the transcriptional activity of the E2F1
promoter is inhibited by Alien through the E2F binding sites.
Since different E2F family members can bind to E2F sites it was
unclear whether the transactivation of E2F1 itself can be
repressed by Alien.
Thus, in a second step to verify whether Alien inhibits the
transactivation function of E2F1, a Gal-E2F1 fusion was used
together with the UAS-reporter (pUAS4x-TATA-Luc) and
Alien expression vector was cotransfected with increasing
Fig. 1. Alien interacts with E2F1 and is recruited to the E2F1 promoter in vivo. (A) Co-IP experiments using for immunoprecipitation (IP) the anti-E2F1 or anti-Alien
antibodies from U-2OS cell extracts and detection of the immunoprecipitate with anti-E2F1 antibody (upper panel) or the anti-Alien antibody (lower panel) in
immunoblotting (IB). Arrows indicate the migration of the E2F1 and Alien proteins, respectively. IgG was used as unspecific and unrelated antibody. (B) ChIP
experiments using LNCaP cells with anti-Alien or as control the anti-androgen receptor antibody as an unrelated antibody (unrelat. AB) and detection of the proximal
E2F1 promoter containing the E2F binding sites (upper panel) or, as control, a 1.3-kb upstream region of the E2F1 gene (lower panel). Schematic view of E2F1 gene
with the location of primers is indicated in the left panel. The arrows in the right panel indicate specific PCR products.
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alone was employed. As expected, transfection of Gal-E2F1
expression plasmid activates the reporter activity. However,
expression of Alien leads to a dose-dependent inhibition of theFig. 2. Alien inhibits E2F1-mediated transactivation and E2F1 gene expression. (A) T
specifically the 3xE2Fwt-luciferase reporter (1.5 μg) containing three E2F binding
binding sites in the same promoter context (E2F1mut-luc) and the empty expression v
arbitrarily as 100%. (B) The Gal-E2F1 fusion is repressed by Alien. The reporter pU
E2F1 fusion in reporter assays. As control the expression vector for Gal alone was us
Increasing amounts of Alien expression vector (0, 0.5, 1, 3 and 6 μg) were co-transf
from the mean of triplicate experiments is shown. (C) Quantitative real-time RT-PC
LNCaP cells stably transfected with Alien or as a control with the empty expression v
mRNA values (black) are depicted. The amount of mRNAwithin the control cells w
indicated.reporter expression indicating that Alien inhibits the transacti-
vation function of E2F1.
Since Alien is recruited to the E2F1 promoter and inhibits
E2F1 transactivation function, we tested whether the endoge-ransient expression of Alien (2 μg) in C33A cells lacking functional pRB inhibits
sites of the E2F1 promoter. As control the reporter with the three mutated E2F
ector were used. The values obtained with the empty expression vectors were set
AS4x-TATA-Luc (1.5 μg) was used to determine the effect of Alien on the Gal-
ed, of which the value without Alien expression vector was set arbitrarily as one.
ected with a constant amount of Gal-E2F1 (1μg) into C33A cells. The deviation
R was used to detect the expression of the endogenous E2F1 gene expression.
ector were employed. Both non-normalized (grey) and via beta-actin normalized
as set as one. The deviation from the mean of two independent experiments is
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purpose LNCaP cells were used for stable transfection with an
Alien expression vector. After selection, stable cell clone pools
were used and analyzed for expression of the endogenous E2F1
gene. Quantitative real-time RT-PCR was employed comparing
the parental cells with stably transfected Alien expression vector
(Fig. 2C). As internal control the beta-actin mRNAwas used for
normalization. Interestingly, cells stably transfected with Alien
exhibited a reduced expression level of endogenous E2F1. This
suggests that Alien inhibits the expression of E2F1.
Taking together, Alien inhibits transcription from the E2F1
promoter through its E2F binding sites, the transactivation of
E2F1 and the endogenous E2F1 gene expression.
4.3. The expression level of Alien is modulated during cell
cycle
To characterize further a possible association of Alien with
the cell cycle, we analyzed whether the endogenous protein
level of this corepressor varies during cell cycle progression.
For that purpose, synchronized HeLa cells, as a model systemFig. 3. Protein expression of Alien is regulated during cell cycle. (A) Synchronized H
for IB using anti Alien peptide antibody and anti-tubulin antiserum as loading cont
normalized to the loading control and the Alien-levels at the G2-phase were set arbitr
distribution of synchronized HeLa cells at different cell cycle stages is indicated by
gap1 to S-phase; S=S-phase; G2=gap2-phase.for cell cycle phase analyses were employed. The cells were
harvested in different cell cycle phases that were controlled by
FACS analysis (Fig. 3C). Subsequently, the expression of Alien
was detected by analyzing cell extracts with immunoblotting
(Fig. 3A) and was normalized versus endogenous tubulin (Fig.
3B). Interestingly, the protein levels of Alien are higher in the
G1, G1/S and G2 phases and lower in M- and S-phase. As
control, the different cell cycle phases were determined by
FACS analysis (Fig. 3C and supplemental data).
Thus, Alien protein levels change during the cell cycle
phases and are highest in the G1, G1/S ands G2 phases.
4.4. Stable transfection of Alien reduces cell proliferation
Next, we considered whether the interaction of Alien with
E2F1 and inhibition of E2F1 gene expression might influence
cell proliferation. First, we have used LNCaP cells with stable
transfected Alien (LNCaP-Alien). Comparing the growth
properties of LNCaP-Alien cells with the parental cells, the
cell pool with stably transfected Alien exhibited about a 2.3 fold
reduced population doubling (Fig. 4A). Besides lower celleLa cells were harvested in different cell cycle states and cell extracts were used
rol. (B) Western blots were quantified densitometrically and signal levels were
arily as 1. The deviation of the mean of two quantifications is indicated. (C) The
FAC Scan analysis. Abbreviations: M=mitosis; G1=gap1-phase; G1/S=border
Fig. 4. Stable integration of Alien reduces cell proliferation. (A) LNCaP cells and LNCaP-Alien cells obtained after stable transfection and selection were compared for
the cell proliferation and population doubling. (B) Tetracycline expression of Alien was achieved using the previously established NIH3T3 cells expressing the tet-
activator. This tet-off system leads to expression of the target gene in the absence of tetracycline [30]. Stable integration of a tetracycline-regulated promoter linked to
AU5-tagged Alien cDNAwas introduced into these cells. The expression of Alien is shown by Western using an anti-AU5-tag antibody (top panel). Lower left panel:
cell number was counted in either the presence or absence of tetracycline. The deviation of the mean of cell number is shown. Lower right panel: cell number of control
cells stably integrated with the control plasmid as negative control [31], in either the presence or absence of tetracycline. *: unspecific band.
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addition, we employed the established tetracycline regulatable
system introduced in the immortalized NIH3T3 cells [30] and
stably transfected Alien. Tetracycline (Tet) removal leads to the
expression of the transfected gene (Tet-off system [38]). Single
cell clones were selected and analyzed for their proliferation
capacity in the absence or presence of tetracycline as assessed
by cell count. In line with the previous data, stably Alien-
transfected cells proliferated significantly less in the absence of
tetracycline compared to cells grown in the presence of
tetracycline (Fig. 4B). As control, cells were stably transfected
with the control expression plasmid [31] (Fig. 4B). The
population doubling was reduced by a factor of 1.5 fold in a
tetracycline-dependent manner. Control cells with stable
transfection of an unrelated gene did not exhibit a change in
proliferation (data not shown). This suggests that the expression
of Alien inhibits cell proliferation also in NIH3T3 cells.
Thus taken together, the data suggest that Alien inhibits
E2F1 gene expression and cell proliferation.
5. Discussion
Based on our previous observation using a proteomic
approach in which the corepressor Alien was identified as a
novel interacting partner of the E2F1 transcription factor we
intended to investigate the possible functional implication of
this interaction.
Corepressors are defined as transcription factors that mediate
or enhance the gene silencing of DNA bound transcriptionfactors [39]. Characteristics of corepressors are that they act in
the cell nucleus at chromatin level, and repress transcription by
interacting with a transcription factor. Also, corepressors
possess a silencing domain that mediates gene silencing.
Corepressors could also play an important role in repressing
the transactivation function of transcription factors. Alien has
been shown to be corepressor for several nuclear receptors such
as TR, VDR and DAX1 mediating gene repression [26–28].
Investigating promoter occupancy in vivo by ChIP assays
revealed that Alien is recruited to the E2F1 promoter in the
genomic region that includes the E2F binding sites. Since Alien
repressed both the reporter encompassing E2F1 promoter
sequences and the endogenous E2F1 gene expression, it
suggests that repression by Alien is mediated through E2F
binding sites. E2F binding sites are characterized by promis-
cuous recruitment of many E2F family members of transcrip-
tion factors, but actually during late G1/S and S phase the E2F1
promoter is occupied and activated mainly by E2F1 and E2F3
in vivo [40].
In the case of E2F1 we here demonstrate that Alien is able to
repress transcriptional activation mediated by the Gal-E2F1
fusion protein. Thus, this indicates that Alien is able to repress
E2F1 activation function when tethered to the E2F1 promoter
sequences. Taken together these data strongly suggest that Alien
is a corepressor for E2F1.
The detailed molecular mechanism by which Alien inhibits
E2F1-mediated transcriptional activity remains unclear. Inter-
estingly, the transcriptional activity of E2F1 is also dependent
on acetylation of E2F1 [15]. It may be based on blocking the
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Alien-associated HDAC activity [26,29] on either chromatin
level, or by de-acetylating E2F1 itself or a combination of these
mechanisms.
It is well established that DNA-bound E2F1 remains re-
pressed during the cell cycle beyond S-phase by direct binding
of hypophosphorylated pRb recruiting chromatin-remodeling
enzymes like among others SIN3 containing histone deacety-
lating complexes [41]. Interestingly, we recently also identified
pRb and its relative p107 as interacting partners for the Alien
corepressor [19]. A pRb pocket domain mutant (pRb706) that
lacks silencing function, thereby, also lacks Alien interaction.
Besides pRb and p107, there are more examples of func-
tionally interacting proteins that are common for Alien and
E2F1. For example Sin3A and HDAC are associated with
Alien and also were found to complex with E2F1 [26,29,42].
Thus, one could imagine that Alien may target a histone-
modifying complex to promoter-tethered E2F1 transcription
factor.
In addition, in the approach demonstrating repression of E2F
promoter activity we employed human cervix carcinoma cells
(C33A) that are known to lack functional pRb [43]. As a
consequence, Alien seems to be able to repress E2F1 promoter
independently from pRb. Such mechanisms have been
described for E2F in association with other proteins such as
for example prohibitin, HP-1γ, Max and others [41] and refs
therein. This is of special interest explaining in part how some
E2F-responsive genes remain repressed during S-phase
(reviewed in [44]). Taken together, Alien may be an ambivalent
protein able to repress E2F1-mediated transactivation in an Rb-
independent fashion, but the existence of a ternary E2F1–
Alien–pRb complex arbitrating E2F1 repression in special
cellular constellations cannot be ruled out.
Furthermore, due to the positive feed back regulation of
E2F1 on expression of its own gene, one can speculate that
the level of Alien-mediated repression of E2F1 may also be
dictated by Alien protein levels at different cell cycle phases.
Therefore, on one hand it is tentative to speculate that higher
Alien protein levels in G1, at the G1/S border and in G2
phase might inhibit more efficiently E2F-responsive gene
transcription. On the other hand, lower Alien expression level
in S-phase may contribute to de-repression of E2F-target
genes. Interestingly, the protein expression profile of E2F1
seems to be inverted to that of Alien with highest levels of
E2F1 in S-phase [24,25]. However, since the E2F1 promoter
is regulated by multiple transcription factors, it is likely that a
combination of these factors regulate the E2F1 gene
expression. The role of lower Alien expression level observed
in mitotic cells still remains unclear and may be unrelated to
the pRb/E2F pathway.
Our data shown here indicate that Alien interacts with E2F1,
is recruited to the E2F1 promoter sequences in vivo and
represses E2F1-mediated transactivation as well as endogenous
E2F1 gene expression. In line with this, stably expressed Alien
reduces cell proliferation. Taken together this suggests that
Alien has the characteristics of a bona fide corepressor for
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